As a novel SH2 inhibitor of STAT5, AC-4-130 was demonstrated to efficiently diminish STAT5 activity in human AML cells lines and primary FLT3-ITD-driven AML cells. This evidence concerns the gene STAT5B and acute myeloid leukemia.